Volume 22, No 6, Jun 2012
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 22 Issue 6, June 2012: 941-944
RESEARCH HIGHLIGHTS
Reprogramming based gene therapy for inherited red blood cell disorders
Xiuling Xu1,*, Jing Qu1,2,*, Keiichiro Suzuki2, Mo Li2, Weizhou Zhang4, Guang-Hui Liu1 and Juan Carlos Izpisua Belmonte2,3
1National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
2Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA
3Center for Regenerative Medicine in Barcelona, Dr. Aiguader 88, 08003 Barcelona, Spain
4Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
Correspondence: Guang-Hui Liu, Weizhou Zhang, Juan Carlos Izpisua Belmonte,(ghliu@ibp.ac.cn; w4zhang@ucsd.edu; belmonte@salk.edu, izpisua@cmrb.eu)
Hematopoietic stem cell transplantation remains the only curative therapy for certain genetic diseases of the hematopoietic system, including some inheritable deficiencies in red blood cells (RBC). Recent advances in induced pluripotent stem cells may open a new era for the cure of such severe genetic RBC diseases.
Cell Research (2012) 22:941-944. doi:10.1038/cr.2012.54; published online 3 April 2012
FULL TEXT | PDF
Browse 1961
